Antiangiogenic Agents in Cancer Therapy
Antiangiogenic Agents in Cancer Therapy
There is substantial preclinical and clinical evidence that angiogenesis plays a role in the development of tumors and the progression of malignancies. Inhibiting angiogenesis has been shown to suppress tumor growth and metastasis in many preclinical models. These benefits have translated to the clinic with both marketed and investigational antiangiogenesis agents. The most prominent target of these compounds is vascular endothelial growth factor (VEGF) and its receptors. However, several other factors are of interest as well. These include integrins, matrix metalloproteinases, and endogenous antiangiogenic factors. Data from late-stage clinical trials support the role of antiangiogenic agents in cancer therapy and the significant role that VEGF plays in angiogenesis. Future research will focus on determining the tumor types and stages that will benefit most from antiangiogenic therapy and combining therapies that target different factors in the angiogenesis pathway.
There is substantial preclinical and clinical evidence that angiogenesis plays a role in the development of tumors and the progression of malignancies. As reviewed by Rakesh Jain in this supplement (see page 7), new tumors cease to grow beyond 1 to 3 cm without an additional blood supply. Once the angiogenic switch has occurred, the formation of new vessels begins, feeding the developing tumor and making it possible for it to progress. The number of new vessels formed, termed microvessel density, correlates with prognosis in many tumor types. This increased blood supply might be expected to aid in the delivery of chemotherapy to the tumor, but such is not the case. The tumor vasculature is irregularly shaped, disorganized, and highly permeable. This permeability contributes to high interstitial fluid pressure within the tumor, which inhibits the effective delivery of chemotherapy to the tumor tissue. The inefficient blood flow associated with this dysfunctional vasculature further impedes the delivery of chemotherapy. In addition, this dysfunctional vasculature can hinder tumor oxygenation, thereby promoting resistance to radiation. These effects of angiogenesis make this abnormal process in tumor development an attractive target for therapeutic intervention. A large number of endogenous pro- and antiangiogenic factors tightly regulate the process. Of these, the most prominent and well researched is vascular endothelial growth factor (VEGF). A phase III trial of the currently marketed monoclonal antibody to VEGF-A (referred to as VEGF), bevacizumab (Avastin), added to conventional cytotoxic chemotherapy showed greater survival in patients with metastatic colorectal cancer.[ 1] Many other agents that target VEGF and other factors in the regulation of angiogenesis are being developed. This article reviews agents currently marketed or in clinical development that target these factors. Current Antiangiogenic Therapies A large number of agents that target angiogenesis are in clinical development. They can be broadly classified as agents that have been developed primarily for their antiangiogenic activity (Table 1), and those that have been developed or used for other biologic effects but also have antiangiogenic activity (Table 2). This review focuses on those that have been developed primarily as antiangiogenic agents. VEGF-Targeted Agents
By far the greatest number of antiangiogenic drugs currently in clinical development target the VEGF pathway. As reviewed by Jain in this supplement, VEGF is crucial in the angiogenic process, making this pathway a logical target. VEGF belongs to a family of seven factors (Table 3). VEGF and its isoforms are the ligands for VEGF receptors (VEGFR)-1 and -2. Although VEGF binds to two receptor tyrosine kinases, VEGFR-1 (also known as Flt-1) and VEGFR-2 (also known as KDR), the angiogenic effects are primarily exerted through binding to VEGFR-2. The binding of VEGF to these receptors on endothelial cells results in receptor dimerization and activation, which stimulates signaling cascades involving phospholipase C, protein kinase C, the Src tyrosine kinases, MAP kinase, phosphatidylinositol-3-kinase (PI3K), Ras GTPase-activating protein, and the Raf-Mek-Erk pathway (reviewed in [4,5]) (Figure 1). Additionally, VEGF binds to the non- tyrosine kinase neuropilin receptors (NRP-1 and NRP-2). NRP-1 can act as a coreceptor for VEGF, and as such potentiates VEGFR-2-dependent endothelial cell mitogenesis. Recently it has also been determined that NRP-1 regulates endothelial cell adhesion to extracellular matrix proteins, independent of VEGFR-2. NRP-1 is also expressed on tumor cells and often is the sole VEGF receptor on these cells. Binding of VEGF to NRP-1 on tumor cells promotes tumor cell survival, proliferation,[ 8] and chemotaxis. The function of NRP-2 is as yet unclear but it is likely involved in lymphangiogenesis. Agents targeted toward VEGF act by antagonizing VEGF itself, blocking its receptors, inhibiting its synthesis, or inhibiting proteins in the VEGF receptor-signaling cascade. Most of these actions are targeted toward vascular endothelial cells; however, direct effects on tumor cells are possible through inhibiting interaction of VEGF with NRP-1 and with VEGFR-2 in the isolated cases in which this receptor is expressed on tumor cells (Figure 2). As reviewed by Jain in this supplement, there are two key mechanisms by which the antagonism of VEGF suppresses tumor growth and inhibits metastasis: prevention of neovascularization[10,11] and improvement of chemotherapy delivery.[ 12]
Despite the promising results with these agents, some in this class have failed in clinical trials due to poor efficacy and safety. Semaxinib (SU5416), which was active against VEGFR-1, -2, PDGFR, Flt-4, and c-kit, was associated with a high incidence of thrombotic events and showed no increase in 1-year eventfree survival in a phase II trial in patients with renal cell carcinoma. Similarly, no recent data have been reported on a related molecule, SU6668, which is active against VEGF, PDGF, and fibroblast growth factor-1 receptors. The reason for the delay or discontinuation of the development of SU6668 is not clear, but phase I trials showed self-inducing clearance, which resulted in difficulty in maintaining pharmacologically active concentrations with the maximum tolerated dose.[29-31] Other VEGF receptor-targeted agents include a raf kinase inhibitor, sorafenib (BAY 43-9006), and a chimeric monoclonal antibody to VEGFR-2, IMC-1C11, with sorafenib being the furthest along in development. In a phase II trial there was a response to sorafenib in 25 (40%) of 63 assessable patients with metastatic renal cell carcinoma. The most common grade 3 adverse events were hand-foot skin reaction, rash, fatigue, and hypertension. Good tolerability was shown with IMC-1C11 in phase I trials, but human antichimeric antibodies developed in half of the patients, and a second-generation human monoclonal antibody is being developed.
- Other VEGF-Targeted Agents- Other agents that act on the VEGF pathway include AE-941 (Neovastat) and enzastaurin (LY317615). AE-941 is a derivative of shark cartilage that prevents VEGF from binding to its receptors and also inhibits matrix metalloproteinase (MMP) activity. AE-941 did not meet its primary end point, longer median overall survival, in a phase III trial in patients with renal cell carcinoma, but significantly longer survival was seen in the subgroup of healthier patients with clear cell histology and only one metastatic site (26.3 months with AE-941 vs 12.6 months with placebo; P = .02). The agent is also very well tolerated.[35,36] Its development continues, and a phase III trial in NSCLC is ongoing.
- Antiangiogenic Factors- Proteins that mimic naturally occurring antiangiogenic factors have been developed. Those on which phase II data are available include recombinant human angiostatin and endostatin. Preliminary phase II data on angiostatin in combination with paclitaxel and carboplatin in patients with NSCLC show partial responses in 39% and stable disease in 39% of 23 patients.[ 39] The duration of response was 8 months or longer in four of these patients. The most common adverse event was rash, in 92% of patients (grade 1 in 75%). There were few adverse events in phase I trials of angiostatin monotherapy, mainly grade 1 or 2 injection-site reactions.[ 40,41] Hemorrhage in central nervous system metastases occurred in two patients, and deep-vein thrombosis in two. Long-term treatment (>1 year in five patients) resulted in no additional treatment-related adverse events. A phase II study of endostatin in patients with advanced neuroendocrine tumors showed stable disease in 62% of patients. The only severe adverse event was myocardial infarction in a patient with prior coronary artery disease.
- Integrin-Targeted Agents- Several molecules have been designed to target αv integrins. Integrins are heterodimeric cell-surface receptors that play an important role in endothelial cell migration, proliferation, and survival.[ 43] Two molecules are in phase II trials: MEDI-522 (Vitaxin) and cilengitide (EMD 121974). MEDI- 522 is a humanized monoclonal antibody to αvβ3. Phase I trials showed an absence of serious adverse events other than infusion-related reactions.[ 44,45] Cilengitide is a peptide that contains the Arg-Gly-Asp (RGD) sequence. This sequence is present on integrins and is a binding epitope that is shared by many integrin ligands. Thus, RGD-containing peptides are thought to antagonize integrin-mediated actions. Phase I trials showed no dose-limiting toxicities.[43,46] Phase II trials of both MEDI-522 and cilengitide are ongoing.
- Other Agents- A number of agents aimed at other targets have also been developed. These include the MMP inhibitor BMS-275291, the heparanase inhibitor PI-88, and a group of agents referred to as vascular- disruptive agents that attack existing tumor vasculature rather than prevent the formation of new vessels. BMS-275291 is a nonhydroxamate MMP inhibitor that has been designed to inhibit only MMPs that are not sheddases. It is thought that the inhibition of sheddases contributes to the arthrotoxicity associated with older hydroxamate MMP inhibitors. Grade 2 or higher musculoskeletal symptoms developed in approximately a third of the patients in two phase II trials.[48,49] The drug was administered in both trials with paclitaxel, which is well known for causing arthralgias; however, the trials were randomized and the trial in breast cancer was halted early because of greater toxicity in the BMS-275291 group. The trial in NSCLC, on the other hand, found no difference in arthrotoxicity between those receiving BMS-275291 and those receiving placebo (both along with paclitaxel and carboplatin), and patient accrual to a phase III trial is ongoing. PI-88 inhibits heparanase, an enzyme that causes the release of proangiogenic factors from the extracellular matrix. Good tolerability and evidence of efficacy with PI-88 in phase I trials has led to continued study.[50,51] A phase II trial in multiple myeloma showed disease stabilization in 39% of patients. Phase II trials in melanoma, liver cancer, and NSCLC are ongoing. Four small-molecule vascular-disruptive agents are in clinical trials. Three of these, combretastatin A4, ZD6126, and AVE8062, cause the destruction of tumor vasculature through tubulin depolymerization of proliferating endothelial cells. The fourth, 5,6-dimethylxanthenone-4-acetic acid, is a flavonoid that induces the release of tumor necrosis factor from intratumoral macrophages. Combretastatin A4 is the furthest along in development, with phase II trials ongoing. The most common dose-limiting adverse event in phase I trials was tumor pain.[53,54] Others were acute coronary syndrome, ataxia, and motor neuropathy.
Enzastaurin is an inhibitor of the protein kinase C-β isozyme, which is activated by VEGF and potentiates the effects of VEGF. It is currently in phase I trials. Agents That Do Not Target the VEGF Pathway
Several investigational antiangiogenic drugs are aimed at targets other than the VEGF pathway, including endogenous antiangiogenic factors, integrin inhibitors, enzyme inhibitors, and vascular-disruptive agents. None of these, however, have yet advanced to phase III clinical trials. Those in phase II trials are discussed here.